SERUM CALPROTECTIN IS NOT PREDICTIVE FOR SUCCESSFUL DOSE REDUCTION OR DISCONTINUATION OF TNF INHIBITORS IN RA PATIENTS WITH LOW DISEASE ACTIVITY

被引：0
|
作者：
Den Broeder, N. [1 ]
Tweehuysen, L. [1 ]
Vogl, T. [2 ]
van Herwaarden, N. [1 ]
van den Hoogen, F. H. J. [1 ,3 ]
Thurlings, R. M. [3 ]
den Broeder, A. A. [1 ]
机构：
[1] Sint Maartensklin, Rheumatol, Nijmegen, Netherlands
[2] Univ Munster, Munster, Germany
[3] Radboudumc, Rheumatol, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.1729
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0120
引用
收藏
页码：526 / 526
页数：1
相关论文
共 50 条
  • [31] RELATIONSHIP BETWEEN CALPROTECTIN SERUM LEVEL, DISEASE ACTIVITY, MATRIX METALLOPROTEINASE-3 CONCENTRATION AND RESPONSE TO ETANERCEPT THERAPY IN RA PATIENTS
    Pchelintseva, A.
    Zhornyak, A.
    Ionichenok, N.
    Panasyuk, E.
    Cherkasova, M.
    Denisov, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 821 - 822
  • [32] The relationship between serum calprotectin levels and disease activity in patients with subacute thyroiditis
    Cengiz, H.
    Demirci, T.
    Varim, C.
    Gonullu, E.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (10) : 3745 - 3751
  • [33] Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy.
    Inciarte-Mundo, Jose
    Victoria Hernandez, M.
    Cabrera-Villalba, Sonia
    Ramirez, Julio
    Cuervo, Andrea
    Ruiz-Esquide, Virginia
    Gonzalez Navarro, Azucena
    Yaguee, Jordi
    Canete, Juan D.
    Sanmarti, Raimon
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1278 - S1279
  • [34] Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement
    Bouman, C. A. M.
    van Herwaarden, N.
    van den Hoogen, F. H. J.
    van der Maas, A.
    van den Bemt, B. J. F.
    den Broeder, A. A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (06) : 597 - 603
  • [35] Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits.
    Kavanaugh, Arthur
    Lee, Susan J.
    Solomon, Daniel H.
    Greenberg, Jeffrey D.
    Kremer, Joel M.
    Soto, Lilian
    Etzel, Carol J.
    Reed, George W.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S603 - S603
  • [36] A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers
    Cristina Pomirleanu
    Codrina Ancuta
    Smaranda Miu
    Rodica Chirieac
    Clinical Rheumatology, 2013, 32 : 665 - 670
  • [37] A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers
    Pomirleanu, Cristina
    Ancuta, Codrina
    Miu, Smaranda
    Chirieac, Rodica
    CLINICAL RHEUMATOLOGY, 2013, 32 (05) : 665 - 670
  • [38] DOSE REDUCTION OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY: A PILOT STUDY
    van Herwaarden, N.
    Herfkens-Hol, S.
    van der Maas, A.
    van den Bemt, B.
    van Vollenhoven, R.
    Bijlsma, J.
    den Broeder, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 886 - 886
  • [39] DISEASE ACTIVITY SCORE (DAS) RESPONSE TO ANTI-TNF IN RA PATIENTS
    Clark, Judith
    Kardash, Sally
    Wong, Ernest
    Hull, Richard
    McCrae, Fiona
    Shaban, Ragai
    Thomas, Lynn
    Young-Min, Steven
    Ledingham, Joanna
    RHEUMATOLOGY, 2012, 51 : 128 - 128
  • [40] Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients
    Kim, S-C
    Lee, Y-S
    Seo, K-K
    Jung, G-W
    Kim, T-H
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2014, 26 (03) : 87 - 93
12345